Business Segments · Royalty Expense

Reportable Segment — Royalty Expense

Amgen Reportable Segment — Royalty Expense increased by 8.9% to $574.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 25.3%, from $458.00M to $574.00M.

Analysis

StatementSegment
First reportedQ1 2024
Last reportedQ3 2025
Metric ID: amgn_segment_reportable_segment_royalty_expense

Historical Data

6 periods
 Q1 '24Q2 '24Q3 '24Q1 '25Q2 '25Q3 '25
Value$386.00M$411.00M$458.00M$440.00M$527.00M$574.00M
QoQ Change—+6.5%+11.4%-3.9%+19.8%+8.9%
YoY Change———+14.0%+28.2%+25.3%
Range$386.00M – $574.00M
CAGR+37.4%
Avg YoY Growth+22.5%
Median YoY Growth+25.3%
Current Streak2 quarters growth

Frequently Asked Questions

What is Amgen's reportable segment — royalty expense?
Amgen (AMGN) reported reportable segment — royalty expense of $574.00M in Q3 2025.
How has Amgen's reportable segment — royalty expense changed year-over-year?
Amgen's reportable segment — royalty expense increased by 25.3% year-over-year, from $458.00M to $574.00M.

Cookie Preferences

We use cookies for analytics. See our Privacy and Cookie Policy.